A PHASE-II TRIAL OF MURINE MONOCLONAL-ANTIBODY 17-1A AND INTERFERON-GAMMA - CLINICAL AND IMMUNOLOGICAL DATA

被引：43

作者：

SALEH, MN ^{[1
]}

LOBUGLIO, AF ^{[1
]}

WHEELER, RH ^{[1
]}

ROGERS, KJ ^{[1
]}

HAYNES, A ^{[1
]}

LEE, JY ^{[1
]}

KHAZAELI, MB ^{[1
]}

机构：

[1] VET ADM MED CTR, BIRMINGHAM, AL 35233 USA

来源：

CANCER IMMUNOLOGY IMMUNOTHERAPY | 1990年 / 32卷 / 03期

关键词：

D O I：

10.1007/BF01771455

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

A group of 15 patients with metastatic colorectal adenocarcinoma received a combination of interferon γ (0.1 mg/m2, days 1-15) and the murine monoclonal antibody 17-1A (400 mg, days 5, 7, 9 and 12). The treatment was tolerated with minimal toxicity. Of the 14 evaluable patients, 13 developed human antibody to murine 17-1A, with 11 patients demonstrating antibody to the variable region of 17-1A (anti-idiotype). Antibody to the variable region was inhibited by 17-1A but not by mouse immunoglobulin. Sera from patients with substantial anti-idiotype reactivity were capable of inhibiting the binding of murine 17-1A to antigen expressing LS174-T cells thus indicating the presence of antibody directed against the 17-1A combining site (mirror-image anti-idiotype). The median survival of the whole group was 56 weeks and there was no correlation between clinical response/survival and the development of anti-idiotype antibody. © 1990 Springer-Verlag.

引用

页码：185 / 190

页数：6

共 33 条

[1]

BALCH CM, 1984, SURGERY, V95, P63

[2] CHANGES IN THE BONE-MARROW OF CANCER-PATIENTS TREATED WITH RECOMBINANT INTERFERON ALPHA-2 [J].